Equities research analysts expect Insys Therapeutics, Inc. (NASDAQ:INSY) to report earnings of ($0.11) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Insys Therapeutics’ earnings, with estimates ranging from ($0.15) to ($0.05). Insys Therapeutics posted earnings of $0.07 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 257.1%. The firm is expected to issue its next quarterly earnings report on Thursday, November 2nd.

On average, analysts expect that Insys Therapeutics will report full year earnings of ($0.25) per share for the current fiscal year, with EPS estimates ranging from ($0.31) to ($0.14). For the next financial year, analysts anticipate that the company will post earnings of ($0.23) per share, with EPS estimates ranging from ($0.42) to $0.08. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Insys Therapeutics.

Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.12. The company had revenue of $42.60 million for the quarter, compared to the consensus estimate of $36.90 million. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.02%. The firm’s revenue was down 38.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.13 EPS.

A number of equities analysts have commented on the stock. Royal Bank Of Canada set a $16.00 target price on shares of Insys Therapeutics and gave the stock a “buy” rating in a research note on Saturday, June 3rd. BidaskClub raised shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 8th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Insys Therapeutics in a research note on Tuesday, July 4th. Piper Jaffray Companies set a $10.00 target price on shares of Insys Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, July 26th. Finally, Zacks Investment Research downgraded shares of Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $13.25.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/16/insys-therapeutics-inc-insy-expected-to-announce-earnings-of-0-11-per-share.html.

Shares of Insys Therapeutics (NASDAQ INSY) traded down 0.75% during trading on Wednesday, reaching $9.22. 547,784 shares of the company traded hands. The stock’s market capitalization is $670.26 million. The firm has a 50 day moving average of $9.58 and a 200 day moving average of $11.21. Insys Therapeutics has a 52 week low of $8.70 and a 52 week high of $15.06.

In related news, major shareholder John N. Kapoor Trust Dated Sept purchased 17,500 shares of Insys Therapeutics stock in a transaction dated Friday, August 11th. The shares were acquired at an average cost of $8.93 per share, with a total value of $156,275.00. Following the purchase, the insider now owns 31,982 shares of the company’s stock, valued at $285,599.26. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Saeed Motahari purchased 5,500 shares of Insys Therapeutics stock in a transaction dated Thursday, August 10th. The stock was bought at an average cost of $8.92 per share, for a total transaction of $49,060.00. Following the completion of the purchase, the chief executive officer now directly owns 15,400 shares in the company, valued at approximately $137,368. The disclosure for this purchase can be found here. 67.90% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in INSY. SG Americas Securities LLC purchased a new stake in shares of Insys Therapeutics in the 2nd quarter valued at approximately $138,000. Voya Investment Management LLC purchased a new stake in shares of Insys Therapeutics in the 2nd quarter valued at approximately $149,000. American International Group Inc. raised its stake in shares of Insys Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock valued at $152,000 after acquiring an additional 953 shares during the period. BNP Paribas Arbitrage SA raised its stake in shares of Insys Therapeutics by 213.2% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,133 shares of the specialty pharmaceutical company’s stock valued at $166,000 after acquiring an additional 8,940 shares during the period. Finally, UBS Asset Management Americas Inc. purchased a new stake in shares of Insys Therapeutics in the 1st quarter valued at approximately $172,000. 25.45% of the stock is currently owned by institutional investors and hedge funds.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get a free copy of the Zacks research report on Insys Therapeutics (INSY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.